The natural characteristics of multiple myelomas showed therapeutic effects of a monoclonal antibody against CD48, which is highly expressed on plasma cells,3 implying that the 2B4–CD48 interaction plays a role in tumor immunity. This evidence concerns the gene CD48 and plasma cell myeloma.